Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Stone, Richard
Item TypeName
Academic Article Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells.
Academic Article Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Academic Article Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Academic Article Inhibition of FLT3 tyrosine kinase: an evolving therapeutic strategy in acute myeloid leukemia
Academic Article PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Academic Article Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
Academic Article A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Academic Article Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
Academic Article The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112.
Academic Article Functional role for protein kinase Cbeta as a regulator of stress-activated protein kinase activation and monocytic differentiation of myeloid leukemia cells.
Academic Article Targeted agents in AML: much more to do.
Academic Article Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
Academic Article After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.
Academic Article Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Academic Article Phase IB study of PKC412, an oral FLT3 kinase inhibito in sequential and simultaneous combination with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML
Academic Article Prognostic factors in AML in relation to (ab)normal karyotype.
Academic Article Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells.
Academic Article Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.
Academic Article Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Academic Article Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
Academic Article A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
Academic Article Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations.
Academic Article AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD.
Academic Article Phase IB study of PKC412, an oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicni and Cytarabine (DA) Induction and High Dose cytarabine consolidation in newly diagnosed adult patients with acute myeloid leukemia (AML under age 61)
Academic Article Smac mimetics: implications for enhancement of targeted therapies in leukemia.
Academic Article Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
Academic Article Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
Academic Article Phase IB study of PKC412, an oral FLT3 kinase inhibitor in sequential and simultaneouos combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (patients) with acute myeloid leukemia (AML) under age 61
Academic Article Role of arachidonic acid metabolism in transcriptional induction of tumor necrosis factor gene expression by phorbol ester.
Academic Article Phospholipase C activates protein kinase C and induces monocytic differentiation of HL-60 cells.
Academic Article High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.
Academic Article Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.
Academic Article FLT-3 tyrosine kinase (TK) inhibition: an emerging therapy in acute myeloid leukemia (AML)
Academic Article Phase I study of PKC412 an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with daunorubicin and cytarabine (DAA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML
Academic Article FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.
Academic Article PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
Academic Article Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Academic Article Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Academic Article Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology.
Academic Article CNS relapse in acute promyeloctyic leukemia.
Academic Article Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.
Academic Article Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Academic Article Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation
Academic Article Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Academic Article Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Academic Article Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Academic Article Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.
Academic Article The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia.
Academic Article All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line.
Academic Article Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
Academic Article Proteomic and genetic approaches identify Syk as an AML target.
Academic Article Inhibition of protein kinase C is associated with a decrease in c-myc expression in human myeloid leukemia cells.
Academic Article Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Academic Article Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
Academic Article FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Academic Article Discovery and characterization of novel mutant FLT3 kinase inhibitors.
Academic Article FLT3 inhibitors in acute myeloid leukemia.
Concept Creatine Kinase
Concept Protein Kinase Inhibitors
Concept Glycogen Synthase Kinase 3
Concept Cyclin-Dependent Kinase Inhibitor p27
Concept Janus Kinase 2
Concept MAP Kinase Signaling System
Concept Protein Kinase C
Concept fms-Like Tyrosine Kinase 3
Concept MAP Kinase Kinase Kinase 1
Academic Article A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
Academic Article SYK regulates mTOR signaling in AML.
Academic Article NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.
Academic Article SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Academic Article MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.
Academic Article AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Academic Article Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
Academic Article Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.
Academic Article De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study.
Academic Article Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells.
Academic Article Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Academic Article Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.
Academic Article New Models of Therapy: When Acute Leukemia Becomes Chronic.
Academic Article Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
Academic Article Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.
Academic Article Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Academic Article The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia.
Academic Article Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
Academic Article Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.
Grant PROTEIN KINASE C BASED ANTILEUKEMIC THERAPY
Grant DIFFERENTIATION SIGNAL TRANSDUCTION IN MYELOID LEUKEMIA
Academic Article Characterization of selective and potent PI3Kd inhibitor (PI3KDIN- 015) for B-Cell malignances.
Academic Article Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML.
Academic Article Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Academic Article Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.
Academic Article Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies.
Academic Article The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Academic Article 3 + 7 + FLT3 inhibitors: 1 + 1 ? 2.
Academic Article Novel Therapeutics in Acute Myeloid Leukemia.
Academic Article Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Academic Article The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Academic Article Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
Academic Article Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
Grant SPORE in Myeloid Malignancies
Academic Article Inhibition of USP10 induces degradation of oncogenic FLT3.
Academic Article Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Academic Article Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.
Academic Article Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
Academic Article Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Academic Article Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Academic Article What FLT3 inhibitor holds the greatest promise?
Academic Article Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Academic Article Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Academic Article The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
Academic Article Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Academic Article Inhibition of the deubiquitinase USP10 induces degradation of SYK.
Academic Article Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
Academic Article A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.
Academic Article Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
Academic Article Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.
Academic Article Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Academic Article BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia.
Academic Article A precision medicine classification for treatment of acute myeloid leukemia in older patients.
Search Criteria
  • Elongation Factor 2 Kinase
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.